Literature DB >> 22754586

Current progress and challenges in HIV gene therapy.

Janet Chung1, John J Rossi, Ulrike Jung.   

Abstract

HIV-1 causes AIDS, a syndrome that affects millions of people globally. Existing HAART is efficient in slowing down disease progression but cannot eradicate the virus. Furthermore the severity of the side effects and the emergence of drug-resistant mutants call for better therapy. Gene therapy serves as an attractive alternative as it reconstitutes the immune system with HIV-resistant cells and could thereby provide a potential cure. The feasibility of this approach was first demonstrated with the 'Berlin patient', who was functionally cured from HIV/AIDS with undetectable HIV-1 viral load after transplantation of bone marrow harboring a naturally occurring CCR5 mutation that blocks viral entry. Here, we give an overview of the current status of HIV gene therapy and remaining challenges and obstacles.

Entities:  

Year:  2011        PMID: 22754586      PMCID: PMC3383045          DOI: 10.2217/fvl.11.113

Source DB:  PubMed          Journal:  Future Virol        ISSN: 1746-0794            Impact factor:   1.831


  111 in total

1.  MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms.

Authors:  Yan Zeng; Rui Yi; Bryan R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-05       Impact factor: 11.205

2.  P-body formation is a consequence, not the cause, of RNA-mediated gene silencing.

Authors:  Ana Eulalio; Isabelle Behm-Ansmant; Daniel Schweizer; Elisa Izaurralde
Journal:  Mol Cell Biol       Date:  2007-04-02       Impact factor: 4.272

3.  Fusion with an RNA binding domain to confer target RNA specificity to an RNase: design and engineering of Tat-RNase H that specifically recognizes and cleaves HIV-1 RNA in vitro.

Authors:  Y F Melekhovets; S Joshi
Journal:  Nucleic Acids Res       Date:  1996-05-15       Impact factor: 16.971

Review 4.  Selective nuclear export mechanism of small RNAs.

Authors:  Soo Jae Lee; Chimari Jiko; Eiki Yamashita; Tomitake Tsukihara
Journal:  Curr Opin Struct Biol       Date:  2010-12-07       Impact factor: 6.809

5.  A region of basic amino-acid cluster in HIV-1 Tat protein is essential for trans-acting activity and nucleolar localization.

Authors:  S Endo; S Kubota; H Siomi; A Adachi; S Oroszlan; M Maki; M Hatanaka
Journal:  Virus Genes       Date:  1989-11       Impact factor: 2.332

6.  Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle.

Authors:  Alan R Brooks; Richard N Harkins; Peiyin Wang; Hu Sheng Qian; Pengxuan Liu; Gabor M Rubanyi
Journal:  J Gene Med       Date:  2004-04       Impact factor: 4.565

7.  Restricted transgene persistence after lentiviral vector-mediated fetal gene transfer in the pregnant rabbit model.

Authors:  Rafael Moreno; Marta Rosal; Itziar Martinez; Felip Vilardell; Juan Ramón Gonzalez; Jordi Petriz; Edgard Hernandez-Andrade; Eduard Gratacós; Josep M Aran
Journal:  J Gene Med       Date:  2008-09       Impact factor: 4.565

8.  Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients.

Authors:  Rafael G Amado; Ronald T Mitsuyasu; Joseph D Rosenblatt; Frances K Ngok; Andreas Bakker; Steve Cole; Nathalie Chorn; Lii-Shin Lin; Gregory Bristol; Maureen P Boyd; Janet L MacPherson; Gregory C Fanning; Alison V Todd; Julie A Ely; Jerome A Zack; Geoff P Symonds
Journal:  Hum Gene Ther       Date:  2004-03       Impact factor: 5.695

9.  Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration.

Authors:  Eugenio Montini; Daniela Cesana; Manfred Schmidt; Francesca Sanvito; Maurilio Ponzoni; Cynthia Bartholomae; Lucia Sergi Sergi; Fabrizio Benedicenti; Alessandro Ambrosi; Clelia Di Serio; Claudio Doglioni; Christof von Kalle; Luigi Naldini
Journal:  Nat Biotechnol       Date:  2006-05-28       Impact factor: 54.908

10.  HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome.

Authors:  Ellen M Westerhout; Marcel Ooms; Monique Vink; Atze T Das; Ben Berkhout
Journal:  Nucleic Acids Res       Date:  2005-02-01       Impact factor: 16.971

View more
  8 in total

1.  Preclinical Assessment of Mutant Human TRIM5α as an Anti-HIV-1 Transgene.

Authors:  Ulrike Jung; Kevin Urak; Maxime Veillette; Marie-Édith Nepveu-Traversy; Quang Toan Pham; Sophie Hamel; John J Rossi; Lionel Berthoux
Journal:  Hum Gene Ther       Date:  2015-08-06       Impact factor: 5.695

2.  A recombinant adenoviral vector with a specific tropism to CD4-positive cells: a new tool for HIV-1 inhibition.

Authors:  Abtin Behmardi; Touraj Farazmandfar
Journal:  Drug Deliv Transl Res       Date:  2022-01-31       Impact factor: 5.671

3.  Transcriptome Analysis Reveals Novel Entry Mechanisms and a Central Role of SRC in Host Defense during High Multiplicity Mycobacterial Infection.

Authors:  Jay Zhang
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

4.  Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor.

Authors:  Orit Wolstein; Maureen Boyd; Michelle Millington; Helen Impey; Joshua Boyer; Annett Howe; Frederic Delebecque; Kenneth Cornetta; Michael Rothe; Christopher Baum; Tamara Nicolson; Rachel Koldej; Jane Zhang; Naomi Keech; Joanna Camba Colón; Louis Breton; Jeffrey Bartlett; Dong Sung An; Irvin Sy Chen; Bryan Burke; Geoff P Symonds
Journal:  Mol Ther Methods Clin Dev       Date:  2014-02-12       Impact factor: 6.698

5.  Modulated expression of the HIV-1 2LTR zinc finger efficiently interferes with the HIV integration process.

Authors:  Sutpirat Moonmuang; Somphot Saoin; Koollawat Chupradit; Supachai Sakkhachornphop; Nipan Israsena; Ruttachuk Rungsiwiwut; Chatchai Tayapiwatana
Journal:  Biosci Rep       Date:  2018-09-07       Impact factor: 3.840

6.  RNase P-associated external guide sequence effectively reduces the expression of human CC-chemokine receptor 5 and inhibits the infection of human immunodeficiency virus 1.

Authors:  Wenbo Zeng; Gia-Phong Vu; Yong Bai; Yuan-Chuan Chen; Phong Trang; Sangwei Lu; Gengfu Xiao; Fenyong Liu
Journal:  Biomed Res Int       Date:  2012-12-27       Impact factor: 3.411

7.  Effective inhibition of human immunodeficiency virus 1 replication by engineered RNase P ribozyme.

Authors:  Wenbo Zeng; Yuan-Chuan Chen; Yong Bai; Phong Trang; Gia-Phong Vu; Sangwei Lu; Jianguo Wu; Fenyong Liu
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

Review 8.  Thirty years of the human immunodeficiency virus epidemic and beyond.

Authors:  Fariba S Younai
Journal:  Int J Oral Sci       Date:  2013-10-18       Impact factor: 6.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.